The mRNA-LNP Platform’s Lipid Nanoparticle Component Used in Preclinical Vaccine Studies is Highly Inflammatory

Sonia Ndeupen et al.

Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side effects remain poorly defined. Here we present evidence that Acuitas’ LNPs used in preclinical nucleo-side-modified mRNA vaccine studies are highly inflammatory in mice. Intradermal and intramuscular injection of these LNPs led to rapid and robust inflammatory responses, characterized by massive neutrophil infiltration, activation of diverse inflammatory pathways, and production of various inflammatory cytokines and chemokines. The same dose of LNP delivered intranasally led to similar inflammatory responses in the lung and resulted in a high mortality rate, with mechanism unresolved. Thus, the mRNA-LNP platforms’ potency in supporting the induction of adaptive immune responses and the observed side effects may stem from the LNPs’ highly inflammatory nature.

Latest articles

Canadian Biotechnology Action Network With this controversial reform proposal, the seed industry...
David Bell The Lancet recently released its long-awaited COVID-19 commission report. The report well...
Euzebiusz Jamrozik The global response to the recent coronavirus pandemic has revealed...
Abdulrahman Koshak et al. Effective treatment for patients with the novel Coronavirus...
James A. Thorp et al. Objectives: Assess rates of adverse events (AE)...
VaxJustice.org The rates of death and injury from Covid-19 never justi ed...

Your donation helps us
stand up for health freedom!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.

Thank you!

The form has been submitted successfully!